Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
3.880
-0.360 (-8.49%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Design Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Design Therapeutics stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 106.19% from the current stock price of 3.88.
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2024.
Analyst Ratings
The average analyst rating for Design Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +3.09% | Aug 6, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $6 → $12 | Hold → Buy | Upgrades | $6 → $12 | +209.28% | May 7, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +3.09% | Mar 20, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +28.87% | Mar 20, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $4 | Hold | Maintains | $7 → $4 | +3.09% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.23
from -0.88
EPS Next Year
-1.14
from -1.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.11 | -0.82 | -0.88 | ||
| Avg | -1.23 | -1.14 | -1.34 | ||
| Low | -1.27 | -1.31 | -1.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.